Superluminal Medicines Raises $60 Million for Obesity Drug Trial

September 03, 2026
The Series B financing will support a Phase 1 trial of a treatment for rare genetic forms of obesity by the end of 2026.

Superluminal Medicines has closed an oversubscribed $60 million Series B financing, the company announced in a press release. The round was led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors including RA Capital Management, Insight Partners, NVIDIA and Eli Lilly and Company.

The funding will support a Phase 1 clinical trial by the end of 2026 for Superluminal's lead program, a selective MC4R agonist for rare genetic forms of obesity and hypothalamic obesity. The company said the drug selectively activates signaling pathways associated with therapeutic effects while limiting side effects.

Superluminal will also use the capital to advance other programs and expand its GPCR discovery platform for endocrine and cardiometabolic diseases. The platform combines structural biology, cryo electron microscopy, small molecule design, predictive toxicity models, machine learning and GPCR biophysics.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/02
MulticoreWare Acquires Simulus Automation for Semiconductor Design
09/02
Konko AI Raises $6 Million for Patient Journey Platform
09/02
Airbility Raises $4.7 Million for AI Counter Drone Aircraft
09/02
Thyme Care Raises Over $125 Million and Forms Thyme Companies
09/02
HiddenLayer Raises $100 Million for AI Security Platform

More from: Life Sciences

09/03
Insilico Medicine Joins HKEX Tech 100 Index
09/03
Unisys Publishes AI Evaluation Framework for Drug Repurposing
09/02
Systech Launches TraceIQ for Pharmaceutical Supply Chains
09/02
Onymos and Vanta Diagnostics Report AI Lab Intake Results
09/02
EpiVax Adds AI Models to ISPRI Immunogenicity Platform

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like